Prospective Surveillance for Very Early Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-15

Study Completion Date

2023-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatocellular carcinoma is one the leading cause of increasing cancer-specific mortality worldwide. Early diagnosis of hepatocellular carcinoma provides opportunity for curative therapeutic approaches and relatively favorable prognosis. Herein, we intended to establish a biosignature for early diagnosis of hepatocellular carcinoma and stratification of risk population for intensive follow-up by implementing biannual follow-up investigation and collecting peripheral blood samples for screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Surveillance of Hepatocellular Carcinoma

NCT05286099

Hepatocellular Carcinoma

UNKNOWN

Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study

NCT00629421

Cirrhosis Hepatocellular Carcinoma

COMPLETED

Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma

NCT07030842

Hepatocellular Carcinoma (HCC)

COMPLETED

Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma

NCT00842647

Hepatocellular Carcinoma

UNKNOWN

The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients

NCT07147335

Cirrhosis Hepotacellular Carcinoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be recruited for 1 year and be follow-up for 3 years. Patients will make active hospital visit for collection of blood samples, which will be analyzed to develop a biosignature at the end of the study to detect very early hepatocellular carcinoma and stratify risk population for intensive follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Hepatocellular

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cirrhosis cohort

Patients with liver cirrhosis.

No interventions assigned to this group

HBV infection cohort

Patients with seropositivity of HBsAg.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

\[1\] Cirrhosis cohort

1. Age within 30 to 75 years.
2. Diagnosis of liver cirrhosis within recent 6 months.



1. Liver biopsy: Metavir score of 4 or Ishak score of 5 to 6.
2. No liver biopsy: Presence of ascites, hepatic encephalopathy, or variceal hemorrhage.
3. Satisfying equal to or more than 2 of below conditions.

* Imaging studies indicating characteristics of liver cirrhosis: irregular liver surface, liver parenchyma particles or nodules, intraperitoneal collateral circulation, or varicose veins with or without splenomegaly (more than 4 cm or 5 ribs).
* Platelet count \< 200 x 10\^9/L.
* Alanine aminotransferase \< 5 folds of normal level and liver hardness \> 12 kPa.
* Gastroesophageal varices from endoscopy or imaging studies.

\[2\] HBV infection cohort
1. Age within 40 to 70 years
2. Chronic HBV infection (seropositive for HBsAg over 6 months).

Exclusion Criteria

1. Cirrhosis cohort

(1) Child-Pugh score of C.

(2) Hereditary metabolic liver diseases.

(3) Presence of HIV-Ab.

(4) Previous diagnosis of active pulmonary tuberculosis.

(5) Diagnosis of malignant tumors before or during hospitalization, including but not limited to hepatocellular carcinoma.

(6) Patients who had received allogeneic blood transfusion or cell therapy within 1 year.

(7) Pregnant women.

\[2\] HBV infection cohort

(1) Autoimmune liver diseases.

(2) Hereditary metabolic liver diseases.

(3) Other chronic liver diseases, such as flukes.

(4) Presence of HCV, HDV, HEV, or HIV infection.

(5) Previous diagnosis of active pulmonary tuberculosis.

(6) Diagnosis of malignant tumors before or during hospitalization, including but not limited to hepatocellular carcinoma.

(7) Patients who had received allogeneic blood transfusion or cell therapy within 1 year.

(8) Pregnant women.

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No